Development of Solid Lipid Nanoparticles for Controlled Amiodarone Delivery

Area of Science:

• Pharmaceutical Nanotechnology
• Drug Delivery Systems

Background:

• Solid lipid nanoparticles (SLNs) are effective lipid-based nanocarriers for drug delivery.
• Amiodarone hydrochloride, an antiarrhythmic drug, exhibits poor oral absorption due to low solubility and high permeability.
• Improving amiodarone's solubility is crucial for effective therapeutic outcomes.

Purpose of the Study:

• To enhance the solubility and oral bioavailability of amiodarone hydrochloride.
• To develop and characterize amiodarone-loaded solid lipid nanoparticles (AMD-SLNs) using Compritol® 888 ATO and Transcutol®.
• To evaluate the pharmaco-technical properties and in vitro dissolution of the developed AMD-SLNs.

Main Methods:

• Hot homogenization followed by ultrasonication was employed to prepare AMD-SLNs.
• Formulations were characterized for size, polydispersity index, zeta potential, entrapment efficiency, and drug loading.
• Advanced techniques including SEM, FTIR, NIR, TGA, and DSC were used for comprehensive analysis.
• In vitro dissolution studies were conducted to assess drug release profiles.

Main Results:

• Six types of AMD-SLNs were successfully prepared with varying sonication parameters.
• The P5 formulation exhibited optimal pharmaco-technical characteristics.
• SEM, FTIR, NIR, TGA, and DSC analyses confirmed the successful encapsulation and stability of amiodarone within the SLNs.
• In vitro dissolution tests indicated a controlled release pattern for amiodarone from the P5 formulation.

Conclusions:

• The developed AMD-SLNs, particularly the P5 formulation, show significant potential for improving amiodarone hydrochloride's oral delivery.
• Solid lipid nanoparticles offer a promising platform for enhancing the solubility and controlled release of poorly soluble drugs like amiodarone.
• Further investigation into oral pharmaceutical products utilizing these optimized AMD-SLNs is warranted.